A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Food immunotherapy practice: Nation differences across Europe, The FIND project




Julkaisun tekijät: Rodriguez del Rio Pablo, Alvarez-Perea Alberto, Blumchen Katharina, Caimmi Davide, Christoph Caubet Jean, Panagiotis Konstantinopoulos Anastasios, Riggioni Carmen, Fassio Filippo, Karakoc-Aydiner Elif, Thuy May Le, Patel Nandinee, Savolainen Johannes, Vazquez-Ortiz Marta, Alvaro Lozano Montserrat

Kustantaja: WILEY

Julkaisuvuosi: 2021

Journal: Allergy

Tietokannassa oleva lehden nimi: ALLERGY

Lehden akronyymi: ALLERGY

Sivujen määrä: 13

ISSN: 0105-4538

eISSN: 1398-9995

DOI: http://dx.doi.org/10.1111/all.15016


Tiivistelmä
Background Food allergen immunotherapy (FA-AIT) practice is known to vary globally. This project aims to identify and characterize European centres performing FA-AIT. Methods An EAACI task force conducted an online survey to gather relevant information regarding FA-AIT practice and setting-specific resources after reviewing the published literature and congress abstracts throughout Europe. Results We identified 102 FA-AIT centres in 18 countries; only Spain (n = 39) and France (n = 16) had >= 10 such centres. Overall, most facilities were hospital-based (77.5%), publicly funded (80.4%) and delivered FA-AIT as routine clinical care (80.4%). On average, departments had 3 allergists/paediatric allergists and 2 nurses. Surveyed centres had provided FA-AIT for a median of 9 years [1-24] to a median of 105 [5-2415] patients. The estimated total number of treated patients was 24875, of whom 41.3% received AIT for milk, 34.2% egg, 12.8% peanut and 11.7% other foods. Anaphylaxis to AIT doses requiring over 4-6 h of observation was reported by 70.6% of centres, ICU admissions by 10.8% and eosinophilic esophagitis by 45.1%. Quality of life and sustained unresponsiveness were evaluated in 20.6% and 54.9% of centres, respectively. The main contraindications for food AIT were severe asthma (57%-63%), eosinophilic esophagitis (56%-48%) and age below 5 years (47%-41%). Conclusions In Europe, FA-AIT is provided mostly in clinical practice. Significant variation is seen in the number of centres per country, facility characteristics and inclusion/exclusion criteria, and in certain aspects of protocols. Potential inequality in access to AIT has been identified as well as the need for education and guidance for treatment standardization.


Last updated on 2021-16-09 at 18:07